Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewZiprasidone hydrochloride
说明： 5-HT2A antagonist; also D2 antagonist; atypical antipsychotic
别名： CP 88059
化学名： 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride
纯度： ≥99% (HPLC)
生物活性 for Ziprasidone hydrochloride
Atypical antipsychotic that displays combined serotonin and dopamine receptor antagonism. Displays high affinity at 5-HT2A receptors with a 5-HT2A/D2 affinity ratio greater than any other clinically available atypical antipsychotics (pKi values are 9.38, 8.88, 8.69, 8.47, 8.32, 8.14, 7.98, 7.49, 7.33 and 6.28 for 5-HT2A, 5-HT2C, 5-HT1D, 5-HT1A, D2, D3, α1, D4, H1 and D1 receptors respectively).
许可信息
Sold for research purposes under agreement from Pfizer Inc.
技术数据 for Ziprasidone hydrochloride
| 分子量 | 449.4 |
| 公式 | C21H21ClN4OS.HCl |
| 储存 | Store at RT |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 122883-93-6 |
| PubChem ID | 219099 |
| InChI Key | NZDBKBRIBJLNNT-UHFFFAOYSA-N |
| Smiles | O=C2CC1=CC(CCN3CCN(C4=NSC5=C4C=CC=C5)CC3)=C(Cl)C=C1N2.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for Ziprasidone hydrochloride
参考文献 for Ziprasidone hydrochloride
参考文献是支持产品生物活性的出版物。
Seeger et al (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined DA and serotonin receptor antagonist activity. J.Pharmacol.Exp.Ther. 275 101 PMID: 7562537
Schmidt et al (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur.J.Pharmacol. 425 197 PMID: 11513838
Fell et al (2005) Investigation into the effects of the novel antipsychotic zipras. on weight gain and reproductive function in female rats. Behav.Brain Res. 160 338 PMID: 15863230
按产品操作查看相关产品
关键词: Ziprasidone hydrochloride, Ziprasidone hydrochloride supplier, 5-HT2A/D2, antagonists, atypical, antipsychotic, Serotonin, 5-HT2A, Receptors, Dopamine, dopaminergic, CP88059, Pfizer, 138982-67-9, CP, 88059, D2, 3085, Tocris Bioscience
3 篇 Ziprasidone hydrochloride 的引用文献
引用文献是使用了 Tocris 产品的出版物。 Ziprasidone hydrochloride 的部分引用包括：
Schulz et al (2012) First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol 167 1480 PMID: 22817643
Canfrán-Duque et al (2015) Curcumin Mitigates the Intracellular Lipid Deposit Induced by Antipsychotics In Vitro. Mediators Inflamm 10 e0141829 PMID: 26517556
Canfrán-Duque et al (2013) Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 54 310 PMID: 23175778
Ziprasidone hydrochloride 的评论
目前没有该产品的评论。 Be the first to review Ziprasidone hydrochloride and earn rewards!
Have you used Ziprasidone hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.